Clinical study supports prediction of chemotherapy benefit by MammaPrint in patients with HR+HER2- early-stage breast cancer
As observed in Miami Breast 2024, Poster 29. This webpage will be updated with new data post SABCS 2024
Clinical study supports prediction of chemotherapy benefit by MammaPrint in patients with HR+HER2- early-stage breast cancer
As observed in Miami Breast 2024, Poster 29
Study Findings
- MammaPrint indices within Low Risk and UltraLow Risk ranges exhibit low chemosensitivity and do not derive significant chemotherapy benefit, consistent with results in MINDACT.
- The increasing chemotherapy benefit observed with increasing MammaPrint risk is consistent with the reduction in recurrence risk reported by Knauer et al. for adjuvant therapy.
- These data indicate the utility of MammaPrint to predict adjuvant CT benefit in patients with HR+HER2- breast cancer.
- The overall chemotherapy relative risk reduction is ~50%.
Study Details
- FLEX (NCT03053193): An ongoing prospective, observational trial that has enrolled >12,000 patients with early breast cancer who received standard of care MammaPrint testing, with or without BluePrint, and consented to clinically annotated full transcriptome data collection.
- Study is based on 475 HR+HER2- patients from FLEX.
- CT+ET N=181
- ET Only N=294
- Logistic regression was used to predict 5-year recurrence risk as a continuous function of the MammaPrint index for chemotherapy treated or endocrine therapy only treated patients separately.
- Clinical characteristics were comparable between patients treated with CT vs. patients treated with ET only.
Always Evolving
Since the FLEX study is ongoing, these data will continue to be expanded and updated.
Explore More
Study Findings
- MammaPrint indices within Low Risk and UltraLow Risk ranges exhibit low chemosensitivity and do not derive significant chemotherapy benefit, consistent with results in MINDACT.
- The increasing chemotherapy benefit observed with increasing MammaPrint risk is consistent with the reduction in recurrence risk reported by Knauer et al. for adjuvant therapy.
- These data indicate the utility of MammaPrint to predict adjuvant CT benefit in patients with HR+HER2- breast cancer.
- The overall chemotherapy relative risk reduction is ~50%.
Study Details
- FLEX (NCT03053193): An ongoing prospective, observational trial that has enrolled >12,000 patients with early breast cancer who received standard of care MammaPrint testing, with or without BluePrint, and consented to clinically annotated full transcriptome data collection.
- Study is based on 475 HR+HER2- patients from FLEX.
- CT+ET N=181
- ET Only N=294
- Logistic regression was used to predict 5-year recurrence risk as a continuous function of the MammaPrint index for chemotherapy treated or endocrine therapy only treated patients separately.
- Clinical characteristics were comparable between patients treated with CT vs. patients treated with ET only.
Always Evolving
Since the FLEX study is ongoing, these data will continue to be expanded and updated.
